Heron Therapeutics, Inc. has announced a major transaction involving the sale of substantially all its assets to CorMedix Inc. This move, detailed in a recent filing, marks a pivotal moment for the company as it seeks to streamline operations and focus on its core competencies.

The proposed transaction, outlined in a preliminary proxy statement, indicates that Heron will sell its assets while retaining certain excluded items, such as its federal income tax net operating loss carryforwards. The agreement, dated November 8, 2026, is expected to significantly alter Heron's business landscape.

Background

Heron Therapeutics, Inc. is a Delaware-based company classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol HRTX. Recent filings indicate that Heron is an accelerated filer, and its fiscal year ends on December 31.

What the Filing Says

The filing states, "This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Heron Therapeutics, Inc. with a proxy statement related to a proposed transaction in which the Company will sell substantially all of its assets to CorMedix Inc., other than certain excluded assets." This highlights the strategic nature of the sale and its implications for both companies.

Impact

This asset sale may affect various stakeholders, including Heron's employees, investors, and partners. The transaction could lead to a shift in focus for Heron, as it aims to enhance its operational efficiency and potentially explore new avenues for growth following the sale.

What's Next

The filing does not say what happens next, but it indicates that further details will emerge as the transaction progresses and as Heron prepares to seek shareholder approval.